Adjuvant atezolizumab-bevacizumab after curative therapy for hepatocellular carcinoma

Detalles Bibliográficos
Autor principal: Kudo, Masatoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10282679/
https://www.ncbi.nlm.nih.gov/pubmed/37351140
http://dx.doi.org/10.21037/hbsn-23-203
_version_ 1785061179967668224
author Kudo, Masatoshi
author_facet Kudo, Masatoshi
author_sort Kudo, Masatoshi
collection PubMed
description
format Online
Article
Text
id pubmed-10282679
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-102826792023-06-22 Adjuvant atezolizumab-bevacizumab after curative therapy for hepatocellular carcinoma Kudo, Masatoshi Hepatobiliary Surg Nutr Editorial Commentary AME Publishing Company 2023-05-22 2023-06-01 /pmc/articles/PMC10282679/ /pubmed/37351140 http://dx.doi.org/10.21037/hbsn-23-203 Text en 2023 Hepatobiliary Surgery and Nutrition. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Editorial Commentary
Kudo, Masatoshi
Adjuvant atezolizumab-bevacizumab after curative therapy for hepatocellular carcinoma
title Adjuvant atezolizumab-bevacizumab after curative therapy for hepatocellular carcinoma
title_full Adjuvant atezolizumab-bevacizumab after curative therapy for hepatocellular carcinoma
title_fullStr Adjuvant atezolizumab-bevacizumab after curative therapy for hepatocellular carcinoma
title_full_unstemmed Adjuvant atezolizumab-bevacizumab after curative therapy for hepatocellular carcinoma
title_short Adjuvant atezolizumab-bevacizumab after curative therapy for hepatocellular carcinoma
title_sort adjuvant atezolizumab-bevacizumab after curative therapy for hepatocellular carcinoma
topic Editorial Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10282679/
https://www.ncbi.nlm.nih.gov/pubmed/37351140
http://dx.doi.org/10.21037/hbsn-23-203
work_keys_str_mv AT kudomasatoshi adjuvantatezolizumabbevacizumabaftercurativetherapyforhepatocellularcarcinoma